Selecta RussiaSite MapContact Us

A New Class of Immunotherapies 

Selecta is a clinical-stage biotechnology company developing novel drugs that use immune modulating nanomedicines to generate antigen-specific immune responses to prevent and treat disease. 

Our proprietary technology platform of Synthetic Vaccine Particles (SVP™) is a product engine for the durable and antigen-specific treatment of undesired immune responses. Our antigen-specific, tolerogenic SVPs can be applied in a variety of therapeutic areas with large unmet medical need, and we are strategically focused on three key applications: inhibition of immunogenicity for protein therapies, treatment of allergies, and treatment of autoimmune diseases.

Through proprietary products and collaborations with leading pharmaceutical companies and research organizations, we are building a pipeline of product candidates to address unmet medical needs in serious and chronic diseases.

Learn More blue_arrow 

News

Tech_Pioneers_2014  Profile red_arrow

  • December 9, 2013 – Successful Pre-clinical Study of SEL-201 As An Antigen-Specific Immune Tolerance Treatment for Patients Receiving Factor VIII Therapy Read More red_arrow
  • December 9, 2013 – USPTO Allows First In a Series of Selecta Patents for Antigen-Specific Immune Tolerance Read More red_arrow
  • August 27, 2013 – Selecta Distinguished as World Economic Forum Technology Pioneer 2014 Read More red_arrow
  • November 28, 2012 – Selecta Biosciences and Sanofi Sign Global Collaboration to Develop Antigen-Specific Immunotherapies Read More red_arrow
  • November 28, 2012 – Selecta (RUS) LLC becomes RUSNANO's first foreign portfolio company in the pharmaceutical sector to open a research center in Russia Read More red_arrow
  • May 9, 2012 – Selecta Biosciences Receives 2012 Edison Award's Gold Medal for Best Pharmaceutical Product Innovation. Read More red_arrow
  • November 21, 2011 – Selecta Biosciences Initiates Phase 1 Clinical Study of SEL-068. Read More red_arrow
  • October 27, 2011– Selecta Announces $47.25 Million Financing. Read More red_arrow
  • October 27, 2011– RUSNANO invests in Selecta Biosciences and BIND Biosciences. Read More red_arrow
  • September 6, 2011 Picture2 – FierceBiotech Names Selecta Biosciences a 2011 Fierce 15 Biotech.  Read More red_arrow

Careers

  • Sr. Process Development Engineer (Watertown, MA). Read More red_arrow

© 2014 Selecta Biosciences, Inc.  |  480 Arsenal St., Building One, Watertown, MA 02472  |  Phone: 617-923-1400  |   Fax: 617-924-3454  |  Email: info@selectabio.com
Privacy Policy  |  Web site designed and developed by RainCastle Communications, Inc.